摘要
目的:分析血小板相关参数和凝血指标在肺癌治疗中的变化及意义。方法:选择75例肺癌患者作为观察组,另选同期接受健康体检的75例健康者作为对照组。观察组接受顺铂+吉西他滨(GP方案)化疗。对比两组患者化疗前后血小板相关参数[血小板压积(PCT)、血小板计数(PLT)、血小板分布宽度(PDW)、平均血小板体积(MPV)]和凝血指标[凝血酶时间(TT)、凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、纤维蛋白原(FIB)、D-二聚体(D-D)]。结果:观察组治疗前PCT、PLT、MPV比对照组高,治疗后比治疗前降低(均P<0.05)。观察组治疗前TT、PT、APTT与对照组相比,差异无统计学意义(均P>0.05);观察组治疗前FIB、D-D比对照组高,治疗后TT、PT、APTT、FIB、D-D均比治疗前低(均P<0.05)。治疗前,Ⅲ-Ⅳ期患者PT、TT显著高于Ⅰ-Ⅱ期,APTT、PLT、PCT、PDW、MPV和D-D显著低于Ⅰ-Ⅱ期(均P<0.05)。治疗后,TNM各分期患者凝血指标、血小板相关参数均较治疗前同TNM分期患者下降显著,且Ⅲ-Ⅳ期患者D-D、PDW低于Ⅰ-Ⅱ期,TT、PCT、PLT高于Ⅰ-Ⅱ期(均P<0.05)。结论:肺癌患者处于血液高凝、血小板活化等病理状态,化疗会进一步加剧凝血功能紊乱,故化疗期间密切监测上述指标变化具有重要意义。
Objective:To analyze the changes and significance of platelet-related parameters and coagulation indexes in the treatment of lung cancer.Methods:75 patients with lung cancer were selected as observation group,and 75 healthy people with physical examination were taken as control group.The observation group received cisplatin+gemcitabine(GP regimen)chemotherapy.The platelet-related parameters[thrombocytocrit(PCT),blood platelet count(PLT),platelet distribution width(PDW),mean platelet volume(MPV)]and coagulation indexes[thrombin time(TT),prothrombin time(PT),activated partial thromboplastin time(APTT),fibrinogen(FIB),D-dimer(D-D)]in the two groups before and after chemotherapy were compared.Results:The PCT,PLT,and MPV of the observation group before treatment were higher than those of the control group,and they were lower after treatment than before treatment(all P<0.05).Compared with the control group,the TT,PT,APTT of the observation group before treatment were not statistically different(all P>0.05);the FIB and DD of the observation group before treatment were higher than those of the control group,and the TT,PT,APTT,FIB,DD after treatment All were lower than before treatment(all P<0.05).Before treatment,the PT and TT of stageⅢ-Ⅳpatients were significantly higher than those of stageⅠ-Ⅱ,and APTT,PLT,PCT,PDW,MPV and D-D were significantly lower than those of stageⅠ-Ⅱ(all P<0.05).After treatment,the coagulation indexes and platelet-related parameters of patients in each TNM stage were significantly lower than those in the same TNM stage before treatment,and the DD and PDW of patients in stageⅢ-Ⅳwere lower than those in stageⅠ-Ⅱ,and TT,PCT and PLT were higher than those in stageⅠ-Ⅱ(all P<0.05).Conclusion:Patients with lung cancer are in pathological conditions such as blood hypercoagulability and platelet activation.Chemotherapy will further aggravate the coagulation disorder.Therefore,it is important to monitor the changes of the above indicators during chemotherapy.
作者
常瑞霞
可春梅
CHANG Ruixia;KE Chunmei(The Sixth People’s Hospital of Zhengzhou,Zhengzhou 450000,China)
出处
《陕西医学杂志》
CAS
2021年第5期610-613,共4页
Shaanxi Medical Journal
基金
河南省医学科技攻关计划项目(2018020848)。
关键词
肺癌
血小板相关参数
凝血指标
化疗
监测
Lung cancer
Platelet-related parameters
Coagulation indexes
Chemotherapy
Monitoring
